Fecal Microbiota Transplantation Among Adult Patients With Hematological Malignancies

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-10-01

Study Completion Date

2030-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In Hungary - in comparison to other member states of the European Union - about 75000 new cases of cancer are diagnosed annually, from which approximately 4500-5000 patients suffer from so-called malignant hematological diseases. This disease group includes various leukemias (blood cancers) and lymphomas (lymph node cancers). Chemotherapy for patients with malignant hematological diseases is particularly difficult to bear, as it affects the entire body, including the "good" gut bacteria living inside, and recovery can take several years. Due to the decrease of the "good" gut bacteria during treatment, patients are more prone to acquiring various difficult-to-treat infections, which can lead to deterioration of quality of life, prolonged hospitalization, and in the worst cases, death. The method outlined in this research plan is called fecal microbiota transplantation, during which stool from a healthy person is introduced into the body of the sick patient. The "good" gut bacteria present in the stool then restore the patient's entire gut flora (the process is somewhat similar to the use of probiotics available on the market, but it is a much more effective method). This research aims to assess the success of fecal microbiota transplantation in adults with malignant hematological diseases over a long-term follow-up period, thus contributing to the restoration of their acceptable quality of life.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

FMT In High-Risk Acute GVHD After ALLO HCT

NCT04139577

Acute Graft-Versus-Host Disease (Gvhd) Grade Hematopoietic Cell Transplantation Fecal Microbiota Transplant

COMPLETED PHASE1

Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation

NCT04935684

Acute Leukemia in Remission Myelodysplastic Syndromes Myeloproliferative Syndrome +4 more

RECRUITING PHASE2

Fecal Microbiota Transplantation in aGvHD After ASCT

NCT03819803

Graft Versus Host Disease in GI Tract

RECRUITING PHASE3

Feasibility, Safety, and Potential Efficacy of Fecal Microbiota Transplantation (FMT) for Gastrointestinal Dysfunction in Children Following Hematopoietic Cell Transplant (HCT).

NCT05664113

Gastro-Intestinal Disorder

RECRUITING PHASE1

Stem Cell Transplantation for Patients With Cancers of the Blood

NCT00467961

CML (Chronic Myelogenous Leukemia) CLL (Chronic Lymphocytic Leukemia) AML (Acute Myelogenous Leukemia) +2 more

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Fecal microbiota transplantation (FMT) is currently a widely accepted method of manipulating enteric microbiome, and is an internationally recommended procedure in the treatment for Clostridioides (formerly Clostridium) difficile (C. difficile) infection. The goal of FMT is to restore physiological gut microbiome through natural competition, by administering a stool graft harvested from a healthy person. FMT not only eliminates C. difficile-induced colitis, but also colonization of multidrug-resistant bacterial/fungal species, and certain types of intestinal epithelial damage occuring in some medical conditions. In recent years due to pleiotropic effects of FMT, scientific interest has turned towards adult patients with malignant hematological diseases, since all of the pathological conditions mentioned earlier occur during clinical care in this population, due to detrimental effects of immuno-chemotherapy. Based on promising preliminary results, FMT could be a successful, easily implementable intervention for these patients in the future.

Therefore, the aim of this study is to perform FMTs in four indication groups among adult patients with malignant hematological diseases treated at South Pest Central Hospital - National Institute of Hematology and Infectious Diseases (Budapest, Hungary), followed by a 180-day follow-up period, during which standardized clinical, laboratory, imaging, and microbiological data are collected. In addition, a high-resolution microbiome analys to monitor microbiological changes of recipient pre-/post-FMT blood and stool samples is planned, in collaboration with Departmental Group of Infectious Diseases and Institute of Medical Microbiology of Semmelweis University (Budapest, Hungary).

This study aims to assess both the bacterial and fungal components of the enteric microbiome in adult patients receiving routine clinical care for malignant hematological diseases, and to explore the potential of manipulating the microbiome through fecal microbiota transplantation (FMT). The hypothesis is that microbiome manipulation with FMT in these patients may induce a successful and sustained response by restoring the physiological intestinal microbiome, a premise that this long-term, comprehensive clinical and microbiological follow-up study seeks to support.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Malignant Hematologic Neoplasm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Eligible patients for inclusion are stratified into different interventional subgroups based on four differenc clinical indications for FMT as intervention:

1. patient group: elimination of documented MDR colonization,
2. patient group: treatment of active C. difficile infection,
3. patient group: enteral microbiome restoration following autologous and allogeneic hematopoietic stem cell transplantation,
4. patient group: treatment of corticosteroid-refractory acute gastrointestinal GvHD (see later).

Control groups not receiving FMT as intervention are selected either: 1) from patients who possess the same clinical severity/stage and clinical indication for FMT, but do not agree to participate in the study or not eligible for technical reasons, or 2) randomly selected from patients without malignant hematological diseases and are hospitalized at our center. Patient recruitment is conducted consecutively, and a 1:2 ratio for case-control matching is followed during inclusion.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

FMT

Patients receiving fecal microbiota transplantation (FMT) for different clinical reasons

Group Type EXPERIMENTAL

Fecal Microbial Transplantation

Intervention Type BIOLOGICAL

The technical implementation of FMT procedure is consistent with the methodological letter issued by the National Public Health Center of Hungary. FMT is performed via nasogastric tube with suspended fresh stool graft obtained from a pre-selected stool donor. Following FMT, the patient is observed for 24 hours at our center. The process is supervised and performed by the lead researcher.

non-FMT

Patients not receiving fecal microbiota transplantation (FMT)

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fecal Microbial Transplantation

The technical implementation of FMT procedure is consistent with the methodological letter issued by the National Public Health Center of Hungary. FMT is performed via nasogastric tube with suspended fresh stool graft obtained from a pre-selected stool donor. Following FMT, the patient is observed for 24 hours at our center. The process is supervised and performed by the lead researcher.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Adult patients (diagnosis age ≥18 years) with malignant hematological disease treated at our center, and
2. Capable of giving written informed consent after decision-making, and
3. Documented patient colonization with MDR bacterial or fungal isolates, or
4. Active C. difficile infection, or
5. Patient has undergone autologous or allogeneic hematopoietic stem cell transplantation, or
6. Ongoing corticosteroid-refractory acute gastrointestinal GvHD.

Exclusion Criteria

1. Active bacterial or fungal bloodstream infection requiring antimicrobial therapy, or
2. Peripheral blood absolute neutrophil count \<0.5 G/l on ≥7 consecutive days before planned FMT with maximum dose of administered G-CSF, or
3. Pressor-refractory septic shock, or
4. Major gastrointestinal bleeding within 7 consecutive days before planned FMT, or
5. Any pathological process inhibiting successful or safe nasogastric tube insertion, or
6. Lack of written informed consent.

Eligible Sex

ALL

Accepts Healthy Volunteers

No